Cargando…
PEGylation of Deferoxamine for Improving the Stability, Cytotoxicity, and Iron-Overload in an Experimental Stroke Model in Rats
Deferoxamine (DFO) is a widely used drug for the treatment of iron-overload-related diseases in the clinic. However, its inherent shortcomings, such as a short plasma half-life and cytotoxicity, need to be addressed to widen its clinical utility. In this study, PEGylated DFO was first synthesized, a...
Autores principales: | Xu, Jiake, Sun, Tong, Zhong, Rui, You, Chao, Tian, Meng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546414/ https://www.ncbi.nlm.nih.gov/pubmed/33102469 http://dx.doi.org/10.3389/fbioe.2020.592294 |
Ejemplares similares
-
Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model
por: Sun, Tong, et al.
Publicado: (2020) -
Exploring atherosclerosis imaging with contrast-enhanced MRI using PEGylated ultrasmall iron oxide nanoparticles
por: Zhang, Ruru, et al.
Publicado: (2023) -
Enhanced antifouling properties of marine antimicrobial peptides by PEGylation
por: Lou, Tong, et al.
Publicado: (2023) -
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018) -
Engineering of the Recombinant Expression and PEGylation Efficiency of the Therapeutic Enzyme Human Thymidine Phosphorylase
por: Karamitros, Christos S., et al.
Publicado: (2021)